Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 41: 1371-1377, 1995;
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Joerger, R. D.
Right arrow Articles by Ebersole, R. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Joerger, R. D.
Right arrow Articles by Ebersole, R. C.

Clinical Chemistry, Vol 41, 1371-1377, Copyright © 1995 by American Association for Clinical Chemistry

Analyte detection with DNA-labeled antibodies and polymerase chain reaction

RD Joerger, TM Truby, ER Hendrickson, RM Young and RC Ebersole
Central Research & Engineering Department, E. I. DuPont Co., Wilmington, DE 19880-0173, USA.

We demonstrate immuno-polymerase chain reaction (PCR) assays for two clinical analytes--human thyroid-stimulating hormone and chorionic gonadotropin (hTSH, hCG)--using DNA-labeled antibodies and PCR for amplification of assay response. DNA-antibody conjugates were synthesized by using heterobifunctional cross-linker chemistries to covalently attach single- or double-stranded DNA labels through amine or sulfhydryl groups on the analyte antibodies. These approaches yielded molecular chimeras possessing both analyte-specific antibody binding and nucleic acid amplification functionalities. Dose-response relationships were demonstrated for immuno-PCR assays of both analytes in a microtiter plate-based, two-antibody sandwich assay format. Detection limits for hTSH (1 x 10(-19) mol, < 1.4 mIU/L) and hCG (5 x 10(-18) mol, 0.025 IU/L) exceeded those of conventional enzyme immunoassays by 2-3 orders of magnitude. We also evaluated various DNA design factors influencing label amplification and assay performance, such as primer sequence, strand number, and DNA length. Our findings, in concert with previous reports, suggest that this hybrid technology could provide the basis for a new generation of ultra-sensitive immunoassays offering multianalyte capabilities.


The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Chem.Home page
S.-H. Huang and T.-C. Chang
Detection of Staphylococcus aureus by a Sensitive Immuno-PCR Assay
Clin. Chem., September 1, 2004; 50(9): 1673 - 1674.
[Full Text] [PDF]

Home page
 Mol. Cell. ProteomicsHome page
K. Machida, B. J. Mayer, and P. Nollau
Profiling the Global Tyrosine Phosphorylation State
Mol. Cell. Proteomics, April 1, 2003; 2(4): 215 - 233.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
K. Saito, D. Kobayashi, M. Sasaki, H. Araake, T. Kida, A. Yagihashi, T. Yajima, H. Kameshima, and N. Watanabe
Detection of Human Serum Tumor Necrosis Factor-{alpha} in Healthy Donors, Using a Highly Sensitive Immuno-PCR Assay
Clin. Chem., May 1, 1999; 45(5): 665 - 669.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
C. P. Price
The Evolution of Immunoassay as Seen Through the Journal Clinical Chemistry
Clin. Chem., October 1, 1998; 44(10): 2071 - 2074.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1995 by the American Association for Clinical Chemistry.